Baseline demographics (n=33)
| Mean age (years)±SD | 65.9±8.2 |
| Male gender, n (%) | 27 (82) |
| Risk factors/medical history, n (%): | |
| Diabetes | 1 (3) |
| Hypertension | 10 (30) |
| Hyperlipidaemia | 19 (58) |
| Current smokers | 4 (12) |
| Family history of IHD | 17 (52) |
| Previous CABG | 0 (0) |
| Previous other PCI | 1 (3) |
| Previous CVA | 1 (3) |
| Indication for PCI, n (%): | |
| STEMI | 7 (21) |
| NSTEMI | 11 (33) |
| Unstable angina | 6 (18) |
| Stable angina | 9 (27) |
| LV systolic function (LVEF), n (%): | |
| Good (LVEF>50%) | 27 (82) |
| Moderate (LVEF 30–50%) | 3 (9) |
| Poor (LVEF<30%) | 2 (6) |
| Unknown | 1 (3) |
| Type of drug-eluting stent: | |
| Paclitaxel-eluting stent | 13 (39) |
| Sirolimus-eluting stent | 7 (21) |
| Everolimus-eluting stent | 1 (3) |
| Zotarolimus-eluting stent | 12 (36) |
| Number of stents (no of vessels), n (%): | |
| 1 (1) | 18 (55) |
| 2 (1) | 7 (21) |
| 2 (2) | 6 (18) |
| 3 (1) | 2 (6) |
| Antiplatelet treatment: | |
| Aspirin 75 mg | 33 (100) |
| Clopidogrel 75 mg | 33 (100) |
| Other medication: | |
| Statins | 33 (100) |
| β blockers | 29 (88) |
| ACE inhibitors/A2RBs | 30 (91) |
| Diuretics | 2 (6) |
| Calcium channel blockers | 6 (18) |
| Oral hypoglycaemic agents | 1 (3) |
| Proton pump inhibitors | 8 (24) |
ACE, angiotensin-converting enzyme; A2RB, angiotensin 2 receptor blocker; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; IHD, ischaemic heart disease; LV, left ventricular; LVEF, left ventricular ejection fraction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.